FindTrial
Sign In

IPI-504

DRUG10 trials

Sponsors

Infinity Pharmaceuticals, Inc., MedImmune LLC, Massachusetts General Hospital

Conditions

Breast CancerCancer of the BreastCancer of the ProstateDedifferentiated LiposarcomaGastrointestinal Stromal TumorsHER2 Positive Breast CancerLung CancerMetastatic Breast Cancer

Phase 1

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
CompletedNCT00113204
Infinity Pharmaceuticals, Inc.Multiple Myeloma
Start: 2005-06-30End: 2007-03-31Updated: 2008-05-20
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
CompletedNCT00276302
Infinity Pharmaceuticals, Inc.Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Start: 2005-12-31End: 2010-11-30Updated: 2011-01-06
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
CompletedNCT00431015
Infinity Pharmaceuticals, Inc.Lung Cancer
Start: 2007-01-31End: 2011-12-31Updated: 2012-12-10
A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
WithdrawnNCT00627627
MedImmune LLCBreast Cancer
Start: 2008-04-30Target: 56Updated: 2010-02-03
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
CompletedNCT01427946
Infinity Pharmaceuticals, Inc.Non-small Cell Lung Cancer
Start: 2011-07-31End: 2014-10-31Updated: 2014-11-13

Phase 2

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
CompletedNCT00564928
Infinity Pharmaceuticals, Inc.Cancer of the Prostate, Prostate Cancer, Prostatic Neoplasms
Start: 2007-11-30End: 2010-07-31Updated: 2012-12-11
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
TerminatedNCT00627419
Infinity Pharmaceuticals, Inc.Metastatic Melanoma
Start: 2008-02-29End: 2009-10-31Updated: 2012-12-10
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
TerminatedNCT00817362
Infinity Pharmaceuticals, Inc.Breast Cancer, Cancer of the Breast, HER2 Positive Breast Cancer +1
Start: 2009-03-31End: 2011-05-31Updated: 2012-12-11
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
WithdrawnNCT00969917
Infinity Pharmaceuticals, Inc.Dedifferentiated Liposarcoma
Start: 2010-01-31End: 2010-12-31Updated: 2015-04-14
IPI-504 in NSCLC Patients With ALK Translocations
TerminatedNCT01228435
Massachusetts General HospitalLung Cancer, Stage IIIb Lung Cancer, Stage IV Lung Cancer
Start: 2010-10-31End: 2012-02-29Updated: 2017-12-04